Drug General Information
Drug ID
D09PUR
Former ID
DAP001519
Drug Name
Simvistatin
Drug Type
Small molecular drug
Indication Hyperlipidaemia [ICD9: 272.0-272.4; ICD10:E78] Approved [536186]
HBV infection [ICD9: 070.2-070.3; ICD10:B16, B18.0, B18.1] Phase 1 [536186]
Company
Merck
Structure
Download
2D MOL

3D MOL

Formula
C12H9F3N2O2
Canonical SMILES
CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O
InChI
1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-
InChIKey
UTNUDOFZCWSZMS-YFHOEESVSA-N
CAS Number
CAS 79902-63-9
PubChem Compound ID
PubChem Substance ID
ChEBI ID
ChEBI:9150
SuperDrug ATC ID
C10AA01
SuperDrug CAS ID
cas=079902639
Target and Pathway
Target(s) 3-hydroxy-3-methylglutaryl-coenzyme A reductase Target Info Inhibitor [536186]
BioCyc Pathway Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate)
Superpathway of cholesterol biosynthesis
Mevalonate pathway
KEGG Pathway Terpenoid backbone biosynthesis
Metabolic pathways
Biosynthesis of antibiotics
AMPK signaling pathway
Bile secretion
NetPath Pathway IL5 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
TSH Signaling Pathway
PANTHER Pathway Cholesterol biosynthesis
PathWhiz Pathway Steroid Biosynthesis
WikiPathways Statin Pathway
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
Activation of Gene Expression by SREBP (SREBF)
SREBF and miR33 in cholesterol and lipid homeostasis
Integrated Breast Cancer Pathway
SREBP signalling
Cholesterol Biosynthesis
References
Ref 536186Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
Ref 536186Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.